AUTOTAC Degradation Technology Development Services

Name: AUTOTAC Degradation Technology Development
Brand: BOC Sciences

BOC Sciences provides end-to-end AUTOTAC degradation technology development services for research teams seeking an autophagy-based strategy to remove disease-relevant intracellular proteins, protein aggregates, and other challenging substrates. Compared with conventional ubiquitin-proteasome degraders, AUTOTAC development places stronger emphasis on p62/SQSTM1 engagement, autophagosome recruitment, lysosomal degradation confirmation, and cellular context-dependent cargo clearance. Our support spans target assessment, target-binding ligand discovery, AUTOTAC molecular design, mechanism validation, degradation profiling, and developability optimization, helping clients move from concept to research-grade candidates with stronger confidence and clearer decision points.

Services

BOC Sciences' Comprehensive AUTOTAC Development Services

Target Suitability and Degradation Feasibility Assessment AUTOTAC is especially attractive for intracellular proteins that are difficult to suppress functionally, prone to aggregation, or poorly addressed by occupancy-driven pharmacology. We evaluate target biology, disease relevance, subcellular localization, aggregation tendency, ligandability, and expected compatibility with autophagy-mediated clearance to determine whether an AUTOTAC strategy is practical and how it should be positioned against other degradation modalities. Target biology and pathology review Ligandability analysis supported by target protein services Degradation route comparison with lysosomal-based degradation technology development Early-stage project risk identification and go/no-go recommendations
Rational AUTOTAC Molecular Design We design AUTOTAC molecules as bifunctional constructs that combine a target-binding ligand with an autophagy-targeting motif, while balancing target engagement, intracellular exposure, and autophagy recruitment efficiency. Our design workflows emphasize binding mode analysis, attachment-site selection, and architecture choices that preserve ligand function after conjugation. Ligand design for target protein Attachment-point selection guided by molecular docking for protein-ligand Autophagy-targeting architecture design for p62-directed degradation Candidate proposal output for parallel synthesis
Structural Modeling and Linker Optimization Although AUTOTAC design is not identical to proteasome-oriented chimeras, linker composition and molecular topology still strongly influence target engagement, subcellular behavior, and degradation performance. We optimize linker length, rigidity, polarity, and conjugation geometry to improve productive p62 recruitment while reducing steric interference and unnecessary molecular burden. Protein structure modeling for target analysis Linker design and optimization services Binding-site analysis with linker binding site selection and design Conformational refinement using molecular dynamics simulation
AUTOTAC Synthesis and Focused Analog Generation We synthesize lead AUTOTAC candidates and focused analog sets to support rapid design iteration. Our chemistry strategy is built around efficient preparation of target-binding fragments, autophagy-targeting modules, and linker variants, enabling systematic exploration of structure-degradation relationships rather than one-off molecule delivery. Lead AUTOTAC synthesis Focused analog series generation Structure-degradation relationship analysis Chemistry troubleshooting for low-yield or unstable intermediates
Cell-Based Degradation and Mechanism Validation AUTOTAC projects succeed only when target loss is accompanied by a clear mechanistic signal consistent with autophagy-lysosome clearance. We establish fit-for-purpose assay cascades to quantify degradation, confirm lysosomal involvement, and distinguish true target removal from transcriptional suppression, nonspecific toxicity, or bulk autophagy artifacts. Western blot and quantitative degradation ability assay Kinetic and spatial profiling with live-cell assay Lysosome-dependence and pathway validation Selectivity, rescue, and functional readout studies
Developability Evaluation and Candidate Prioritization Because AUTOTAC molecules can become structurally demanding, early attention to physicochemical and cellular performance is essential. We help clients prioritize molecules with the best balance of degradation activity, permeability, stability, and assay robustness to support downstream research decisions and follow-on optimization. Solubility and formulation risk assessment via solubility and stability Exposure and property prediction using ADME and toxicity prediction Multi-parameter ranking of AUTOTAC leads Research candidate nomination packages

Have You Encountered These Challenges in AUTOTAC Development?

No validated strategy for converting a known binder into an efficient AUTOTAC degrader
Difficulty balancing target affinity, p62 recruitment, and whole-molecule properties
Unclear whether observed target reduction is true lysosomal degradation
Weak activity against aggregation-prone proteins in disease-relevant cell models
Poor solubility, permeability, or intracellular exposure during optimization

Tell Us Your Challenge

Contact us to discuss an AUTOTAC strategy tailored to your target class, disease area, and assay system

Submit Inquiry

Challenge Solving

Our Solutions for Key AUTOTAC Development Challenges

AUTOTAC programs often fail not because the concept is weak, but because the project lacks a disciplined workflow connecting target biology, ligand engineering, mechanistic validation, and property optimization. Our integrated platform is designed to solve these issues in a practical, decision-oriented manner.

Solution for Difficult or Aggregation-Prone Targets For proteins that are hard to inhibit or prone to pathogenic accumulation, we evaluate whether AUTOTAC offers a more suitable route than conventional degrader modalities. We also help define target hypotheses for projects related to aggregate-prone proteins, intracellular scaffolds, and disease-linked misfolded species, including programs adjacent to protein degradation strategies for neurodegenerative diseases.
Solution for Molecular Design Uncertainty When a client has a binder but no validated degrader architecture, we build parallel design hypotheses around attachment vectors, linker classes, and autophagy-targeting motifs. This lets teams compare AUTOTAC candidates with adjacent lysosomal degrader modalities such as AUTAC degradation technology development and ATTEC degradation technology development to sharpen design direction early.
Solution for Mechanism Confirmation Apparent target loss is not enough. We establish mechanism-focused studies to verify lysosomal dependence, autophagic involvement, dose dependency, time dependency, and target-specific clearance. This gives clients stronger confidence that their lead series is acting through the intended biology rather than indirect cellular stress responses.
Solution for Candidate Prioritization We integrate degradation depth, potency, selectivity, intracellular behavior, and developability into a single ranking framework so teams can decide which compounds deserve further chemistry. This is particularly valuable when AUTOTAC programs generate a small number of clear degraders alongside many binders with incomplete or unstable cellular responses.

Choose BOC Sciences to Build a More Actionable AUTOTAC Development Strategy

We help discovery teams translate autophagy-based degradation concepts into practical research workflows, from target selection and molecular design to mechanism-confirmed degradation data and optimized lead series.

Talk to Our Experts

Client Solutions

Our AUTOTAC Solutions Support Diverse R&D Organizations

Academic Laboratories and Research Institutes

Academic teams often need a reliable AUTOTAC workflow to test biological hypotheses around protein quality control, aggregate clearance, and mechanistic disease biology. We support these projects with flexible design, assay setup, and data packages suitable for early discovery and publication-oriented research.

Emerging Biotech Companies

Biotech teams typically need fast technical de-risking: can this target be degraded, what chemistry direction is most promising, and which assays are worth scaling? Our AUTOTAC services help generate those answers efficiently so clients can advance platform hypotheses and target-focused programs with better resource discipline.

Pharmaceutical Discovery Teams

For pharma groups evaluating next-generation degraders, AUTOTAC can provide an alternative path for intracellular proteins that are poorly served by classical proteasome-based systems. We support comparative feasibility assessment, lead generation, and mechanistic validation to enable informed portfolio decisions.

CROs and Technical Service Providers

When partner organizations need specialized support in autophagy-oriented degrader design, assay development, or mechanistic studies, we provide modular AUTOTAC services that can complement existing medicinal chemistry and biology capabilities.

Get a Quote

Workflow

End-to-End AUTOTAC Development Workflow

01

Project Intake and Technical Scoping

We collect target information, known ligands, disease context, desired degradation outcome, preferred cell models, and project constraints.

02

Feasibility Assessment and Route Selection

We assess whether AUTOTAC is appropriate for the target and define the most practical design and validation path.

03

Ligand Review and Design Strategy

Existing binders or new ligand concepts are evaluated for conjugation compatibility, binding retention, and molecular expansion tolerance.

04

AUTOTAC Architecture Design

We generate candidate designs covering target-binding ligand, autophagy-targeting module, linker type, and attachment geometry.

05

Synthesis of Lead and Analog Series

Lead molecules and focused analog sets are synthesized for iterative structure-degradation analysis.

06

Degradation Screening and Mechanism Validation

Compounds are tested for degradation depth, kinetics, selectivity, and lysosome-dependent mechanism in fit-for-purpose assays.

07

Optimization and Developability Assessment

We refine chemistry using activity and property data to improve potency, intracellular performance, and practical usability.

08

Candidate Recommendation and Data Delivery

Final reports summarize design rationale, assay findings, key liabilities, and recommended next-step molecules.

Advantages

Advantages of AUTOTAC Degradation Technology

Suitable for Autophagy-Oriented Target Removal

AUTOTAC provides a rational route for intracellular targets that may benefit from autophagy-lysosome clearance rather than classical proteasomal processing.

Relevant to Aggregate-Prone and Misfolded Proteins

The technology is particularly attractive for research programs involving protein aggregation, aberrant accumulation, or difficult-to-clear intracellular species.

Expands Discovery Options Beyond Occupancy-Driven Inhibition

Instead of merely blocking protein function, AUTOTAC aims to remove the target itself, which can open a broader experimental space for mechanism studies and lead discovery.

Valuable for Next-Generation Degrader Research

AUTOTAC complements other targeted degradation modalities and helps teams explore where autophagy-mediated clearance may outperform more established degrader formats.

Applications

Research Applications Supported by Our AUTOTAC Platform

Neurodegeneration and Protein Aggregation Research

Clearance studies for Tau-related pathogenic species
Programs related to α-synuclein and other aggregation-prone proteins
Mechanistic research on intracellular protein quality control
Discovery support for difficult CNS degradation concepts

Oncology Research

Exploration of autophagic degradation strategies for hard-to-drug oncogenic proteins
Research support for intracellular signaling and mutant oncoprotein programs
Comparative studies alongside KRAS-targeted degradation approaches
Evaluation of degradation-driven pharmacology beyond inhibition

Chemical Biology Tool Development

Target validation through induced protein removal
Probe development for autophagy-mediated degradation studies
Mechanistic comparison with other bifunctional degrader technologies
Discovery support for novel intracellular cargo-clearance concepts

Platform Expansion and Modality Comparison

Head-to-head evaluation of AUTOTAC versus alternative degrader formats
Triage of targets for autophagy-lysosome or ubiquitin-proteasome routes
Design-space mapping for target, linker, and assay strategy selection
Support for next-generation TPD platform building

Case Study

Client Success Stories: AUTOTAC Degradation Technology Development

Project Background

A neuroscience-focused client had a small-molecule binder that recognized β-sheet-rich Tau aggregates in a fluorescence polarization assay, but the compound alone could not produce meaningful aggregate clearance in neuronal cell models. The team wanted to determine whether an AUTOTAC design could convert this binder into a degrader capable of reducing insoluble Tau species while preserving sufficient cell compatibility for follow-up biology studies.

Our Support

We first reviewed the binder's attachment vectors and identified two positions likely to tolerate conjugation without major affinity loss. Based on this analysis, we designed 18 AUTOTAC candidates spanning 3 linker classes and multiple topologies. In SH-SY5Y-derived Tau aggregation models, the initial set showed wide performance differences: several compounds retained binding but failed to reduce aggregated Tau, while a smaller subset produced clear concentration-dependent target loss. We then prioritized 6 molecules for a second optimization round focused on linker polarity and spatial presentation. The best-performing lead reduced detergent-insoluble Tau by approximately 68% at 1 μM after 24 hours, while maintaining greater than 80% cell viability under the same assay conditions. Rescue and inhibitor studies further supported a lysosome-dependent degradation mechanism rather than simple aggregation interference.

Client Outcome

The client received a short list of mechanism-supported AUTOTAC leads, structure-degradation relationship guidance, and a clearer chemistry direction for expanding the program toward more advanced CNS-oriented optimization.

Project Background

An oncology client was exploring autophagy-based degrader strategies for a KRAS-centered discovery effort and needed an experimental framework to determine whether AUTOTAC chemistry could generate measurable target loss in mutant KRAS cellular systems. The key challenge was not only molecule design, but also building a screening cascade that could distinguish true degradation from pathway perturbation or indirect cytotoxicity.

Our Support

We began with target-context analysis and selected a matched cell panel containing KRAS-mutant and comparator lines with different basal signaling profiles. The team then designed and synthesized 24 AUTOTAC-style constructs based on two target-binding chemotypes and several linker variants. Primary screening used target-level immunoblotting together with viability gating and phospho-signaling controls. Eight compounds advanced to deeper profiling, where we added time-course analysis, live-cell imaging, and lysosomal pathway interrogation. Through iterative refinement, one series consistently achieved more than 55% KRAS reduction at sub-micromolar concentrations in the lead mutant line, while weaker analogs revealed which attachment geometry and linker polarity features were detrimental. Rather than delivering a single nominal hit, the project produced a ranked design map that clarified which chemistry directions were worth continuing and which should be deprioritized.

Client Outcome

The client obtained a validated AUTOTAC screening workflow, a prioritized lead series, and a practical decision package for the next round of medicinal chemistry and mechanistic biology work.

Why Choose Us

Why Choose BOC Sciences for Your AUTOTAC Project?

Mechanism-Oriented AUTOTAC Development

We focus not only on making molecules, but on proving whether they truly drive autophagy-mediated target degradation.

Integrated Chemistry and Biology Workflow

Our teams connect target assessment, molecular design, synthesis, degradation testing, and developability review in one coordinated process.

Strong Fit for Challenging Targets

We help clients investigate targets that are difficult to inhibit, aggregation-prone, or poorly served by standard degrader templates.

Flexible Project Models

Whether you need feasibility analysis, AUTOTAC design, mechanism validation, or a complete discovery workflow, our service modules can be adapted to your stage and goals.

Decision-Ready Data Packages

We deliver interpretable data that help clients understand why a series works, where it fails, and what to optimize next.

Efficient Progression from Concept to Lead Series

Our goal is to shorten the path from an AUTOTAC idea to a research-grade set of compounds with credible mechanistic support.

Frequently Asked Questions (FAQ)

Frequently Asked Questions

Still have questions?

Contact Us

What Is AUTOTAC Technology?

AUTOTAC technology is a targeted degradation strategy based on the autophagy-lysosome pathway. Rather than simply inhibiting the activity of a target protein, AUTOTAC is designed to direct the target into the cell’s autophagic clearance machinery, enabling removal of the protein itself. Compared with conventional small-molecule inhibitors, AUTOTAC is particularly relevant for proteins that are difficult to modulate through occupancy-driven inhibition, prone to pathological accumulation, or closely associated with disease progression. For drug discovery teams, AUTOTAC offers a differentiated development path beyond classical inhibitors and some traditional degrader approaches, helping expand the range of tractable targets. BOC Sciences provides integrated support for AUTOTAC projects, from target assessment and molecular design to degradation validation and optimization, helping clients advance programs more systematically.

What R&D Challenges Is AUTOTAC Best Suited to Address?

AUTOTAC is especially well suited for targets that are not adequately addressed by traditional inhibitors, such as proteins that accumulate abnormally, pathogenic aggregates that are difficult to clear, targets for which occupancy-driven inhibition produces limited benefit, or programs where direct removal of the protein is expected to generate a more meaningful biological effect. For drug development clients, the value of AUTOTAC lies not only in offering a new intervention strategy, but also in expanding the accessible space for targets that have historically been difficult to drug or difficult to validate mechanistically. BOC Sciences can support early feasibility assessment based on target biology, ligand availability, degradation potential, and screening strategy, helping clients determine whether AUTOTAC is a worthwhile path before committing significant resources.

What Is the Biggest Technical Challenge in AUTOTAC Development?

The main challenge in AUTOTAC development is usually not the synthesis of a bifunctional molecule itself, but the need to balance several critical factors at the same time, including target-binding performance, autophagy recruitment efficiency, overall molecular properties, and true intracellular degradation activity. In many projects, compounds can still bind the target but fail to induce robust degradation, or they appear to reduce protein levels without clear evidence that the intended autophagy-lysosome pathway is responsible. As a result, experienced drug discovery teams are often most concerned with whether the design logic is credible, whether the validation strategy is rigorous, and whether the optimization path is clear. A capable service partner must be able to integrate molecular design, mechanism confirmation, and property optimization rather than focusing on only one experimental dimension.

How Can You Tell Whether an AUTOTAC Molecule Really Works?

A truly effective AUTOTAC molecule cannot be judged solely by reduced endpoint protein levels. A robust evaluation should include degradation depth, concentration dependence, time dependence, impact on cell health, pathway specificity, and clear evidence of lysosome-dependent activity. For professional drug discovery teams, the most valuable data are those that support the conclusion that the molecule is removing the target through the intended mechanism and that can also guide the next round of structural refinement. BOC Sciences can build stage-appropriate validation cascades for AUTOTAC programs, from early degradation screening to mechanism-focused follow-up studies and multi-parameter comparison of lead candidates, helping clients identify which series truly deserve continued investment rather than relying on superficial positive signals.

Can Existing Lead Binders Be Optimized into AUTOTAC Molecules?

Many clients already have active target binders, fragment hits, or early lead compounds, and these can often provide a strong starting point for AUTOTAC development. The key question is not whether the ligand is simply available, but whether it contains a reasonable attachment site, whether target engagement can be preserved after conjugation, and whether the resulting bifunctional molecule can still maintain acceptable intracellular behavior. In other words, an existing binder cannot automatically be translated into an AUTOTAC molecule without careful structure-activity assessment and iterative design. BOC Sciences can help clients evaluate conjugation vectors, perform structural modeling, design AUTOTAC candidates, build analog series, and validate cellular degradation, turning existing chemical assets into more development-ready AUTOTAC leads.